-
公开(公告)号：US20180200298A1
公开(公告)日：2018-07-19
申请号：US15817002
申请日：2017-11-17
申请人： Fred Hutchinson Cancer Research Center , Seattle Children's Hospital, dba Seattle Children's Research Institute
IPC分类号： A61K35/17 , C07K16/40 , C07K14/705 , C07K16/32 , C07K16/28 , C07K14/715 , C07K14/725
摘要： The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
-
公开(公告)号：US10780118B2
公开(公告)日：2020-09-22
申请号：US14422640
申请日：2013-08-20
IPC分类号： A61K35/17 , C07K14/705 , C07K14/725 , C07K14/715 , C07K16/28 , C07K16/32 , C07K16/40
摘要： The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
-
公开(公告)号：US10736918B2
公开(公告)日：2020-08-11
申请号：US15817002
申请日：2017-11-17
IPC分类号： A61K35/17 , C07K14/705 , C07K14/725 , C07K14/715 , C07K16/28 , C07K16/32 , C07K16/40
摘要： The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
-
公开(公告)号：US20200078405A1
公开(公告)日：2020-03-12
申请号：US16657666
申请日：2019-10-18
申请人： Fred Hutchinson Cancer Research Center , Seattle Children's Hospital, dba Seattle Children's Research Institute
IPC分类号： A61K35/17 , C07K16/40 , C07K16/32 , C07K16/28 , C07K14/715 , C07K14/705 , C07K14/725
摘要： The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
-
公开(公告)号：US20210052649A1
公开(公告)日：2021-02-25
申请号：US17015995
申请日：2020-09-09
申请人： Fred Hutchinson Cancer Research Center , Seattle Children's Hospital, dba Seattle Children's Research Institute
IPC分类号： A61K35/17 , C07K14/705 , C07K14/725 , C07K14/715 , C07K16/28 , C07K16/32 , C07K16/40
摘要： The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
-
公开(公告)号：US20220169723A1
公开(公告)日：2022-06-02
申请号：US17329115
申请日：2021-05-24
发明人： Stanley R. Riddell , Lingfeng Liu
IPC分类号： C07K16/28 , A61K38/17 , A61K35/17 , C07K14/705 , C07K14/725 , A61K38/20 , A61K35/545 , C12N5/0783 , G01N33/569
摘要： The present disclosure relates to tagged chimeric effector molecules and receptor molecules thereof for genetically engineering a host cell, wherein the recombinant host cell can be identified, isolated, sorted, induced to proliferate, tracked or eliminated. For example, a T cell may be recombinantly modified for use in adoptive immunotherapy.
-
公开(公告)号：US10828352B2
公开(公告)日：2020-11-10
申请号：US15521794
申请日：2015-10-27
IPC分类号： A61K39/00 , C07K14/725 , A61K39/12 , A61K35/17 , A61K35/15 , A61K45/06 , C07K14/705 , C07K16/30 , C07K16/28 , A61K48/00
摘要： The present disclosure provides compositions and methods for boosting, augmenting or enhancing the efficacy of the adoptive cellular immunotherapy by using modified T cells expressing an antigen binding protein in conjunction with modified cells (such as hematopoietic progenitor cells, modified human immune system cells or a combination thereof) expressing the antigen specifically bound by the antigen binding protein of the modified T cells.
-
8.发明申请公开(公告)号：US20180243386A1
公开(公告)日：2018-08-30
申请号：US15903214
申请日：2018-02-23
IPC分类号： A61K39/00 , C12N5/0783 , A61K35/17 , G01N33/50
CPC分类号： A61K39/00 , A61K35/17 , A61K2039/515 , A61K2039/57 , A61K2039/572 , C12N5/0636 , C12N5/0638 , C12N2501/599 , G01N33/505 , G01N2333/54 , G01N2333/70557
摘要： This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and/or IL-18Rα and the capacity to rapidly efflux the fluorescent dye Rh123.
-
公开(公告)号：US20230158164A1
公开(公告)日：2023-05-25
申请号：US17601611
申请日：2020-04-04
发明人： Antonio Mario Querido Marcondes , Peter Benedict Kirk , Takahiro Miyazaki , Cameron J. Turtle , Stanley R. Riddell , Cassie K. Chou , Simon P. Fräßle
CPC分类号： A61K47/642 , A61K35/17 , C07K16/2803 , A61P35/00 , A61K9/0019 , A61K38/1774 , C07K2317/24
摘要： Provided are methods and compositions directed to the treatment of an individual having cancer by (i) administering to the individual an adoptive cellular immunotherapy composition comprising CAR T cells and (ii) administering to the individual an interleukin-15 receptor agonist, such as, for example, a long-acting interleukin-15 receptor agonist.
-
公开(公告)号：US20210147540A1
公开(公告)日：2021-05-20
申请号：US17157810
申请日：2021-01-25
IPC分类号： C07K16/28 , G01N33/574
摘要： The present disclosure relates to anti-ROR1 binding proteins, including those that bind to a ROR1 or portion thereof such as an intracellular C terminal portion of a ROR1 protein, and the use of such binding proteins in immunohistochemical and diagnostic methods. Related kits and methods of using the binding proteins are also provided, as are methods of treatment of subjects having diseases or conditions determined to be candidates for such treatments by the binding proteins or methods of this disclosure.
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.029 秒)
